Kaival Brands International (NASDAQ: KAVL) stock is attracting bullish attention, and for excellent reasons. A series of updates shows that its business momentum is doing something most smallcap ENDS sector players aren’t- growing. In fact, at last print, KAVL stock is higher by over 40% YTD, a move supported by a major partnership deal inked with tobacco industry giant Philip Morris (NYSE: PM), earning a stay of order from a U.S. District Court, and extending a critical marketing deal for the development and distribution of electronic nicotine delivery system (ENDS) products in markets outside the U.S., subject to regulatory assessment. Any one of those events should be enough to help sustain bullish momentum.
But investors and KAVL don’t need to rely on just one. Instead, both can benefit from the combined strength inherent to those updates. And they work together to do more than keep a multi-billion-dollar sales opportunity in its crosshairs; parts could leave the competitive landscape thin, which could transform small-cap KAVL into a revenue-generating juggernaut.
A contributor to that goal is its announced partnership with Philip Morris S.A. That deal puts KAVL alongside an industry behemoth, with the two working together to launch PMPSA’s custom-branded self-contained e-vapor product, VEEBA, which will be made available for sale in Canada with royalties due to KBI pursuant to the international licensing agreement. But as noted, that wasn’t the only piece of material news published by KAVL.
Video Link: https://www.youtube.com/embed/jwjXKTjYPAw
One Of The Few ENDS Players Standing
In Q3, KAVL announced that the U.S. Court of Appeals for the Eleventh (11th) Circuit ruled in favor of Bidi Vapor in its appeal of the U.S. Food and Drug Administration’s (“FDA”) Marketing Denial Order (“MDO”) issued to the non-tobacco flavored BIDI Sticks. In a big win, the court set aside or vacated the MDO and remanded the PMTAs back to FDA for further review. In addition to keeping Bidi products available to sell, the FDA entered the tobacco-flavored Classic BIDI® Stick into the final Phase III scientific review, which could ultimately lead to untethered marketing approval and open the door to a massive U.S. market.
That opportunity could target billions in sales, considering that the FDA virtually took nearly every competing ENDS product off the market. Yes, small-cap KAVL, with its BiDi products lineup, is one of the few companies left standing to serve massive consumer demand. And based on the countless documents submitted by KAVL showing its unwavering commitment to only market its products to consumers of legal consumption age, that may remain the case.
Keep in mind that the FDA isn’t playing favorites. They removed competitor Juul’s products from the markets and secured a $438 million settlement over that company’s marketing its product to teens. Of utmost interest on the part of the FDA is making sure that ENDS products are only marketed to people of legal age and that they don’t make misleading claims. KAVL does neither, which is why ENDS players and wannabes are paying attention to KAVL.
A Sector Now Ripe For The Taking
Indeed, the long reach and strength of the FDA changed the ENDS sector in a single swoop. And things haven’t eased. Increasingly restrictive and often ambiguous legislation is still shaking the entire ENDS sector, with federal regulators determined to keep tobacco and nicotine products away from the hands of young adults. Those are great intentions. However, their inconsistent intervention and unclear regulatory guidelines have all but extinguished a multi-billion-dollar flavored electronic delivery systems market. Many small and large domestic brands have simply been unable to survive the challenges imposed by the FDA, with mom-and-pop vapor shops closing their doors across the nation.
KAVL is alive and well. They remain one of the few companies able to market ENDS products by meeting the high expectations of regulatory agencies and showing the court its plan and intention to stay compliant. But it’s not only about marketing. The FDA wants companies’ claims about its products to be accurate, a critical differentiation keeping KAVL in the game. Notably, most KAVL competitors relying on flavored products have failed to submit the required PMTA documents. The worse news for them is that many may not have the means to get a second chance, with the costs associated with providing the required documentation and plans prohibitive to most brands. KAVL has already cleared that hurdle.
Better still, while the U.S. markets may be back in play, unlike many of its peers, KAVL never planned to rely on a single market. Make no mistake, full product access in the U.S. could generate millions in revenues. But access to global sales can put billions of potential revenues into play. The excellent news there- KAVL is equipped and able to capitalize on those enormous overseas market opportunities.
Thus, as KAVL prepares to fully re-engage the U.S. market with its non-flavored BIDI Vapor products, investors can’t discount the opportunity being targeted now by KAVL’s entire products portfolio, enabling them to seize international opportunities that are unreachable by competitors focused only on domestic sales.
That initiative to get bigger faster is already underway.
Exploiting International Markets
KAVL understands the stakes, and it’s crucial for investors to know that the rest of the world isn’t bound to the FDA’s flavored-ENDS prohibition. The revenue-generating opportunities from international markets are massive. They, too, are firmly committed to the safe sale and marketing of goods; they also are more considerate of letting the sector manage itself. Of course, already checking the right boxes, that’s excellent news for KAVL, which is positioned with ENDS products able to capture sales across much of the globe. Even better for KAVL is that global marketing approvals are increasing, with KAVL being no stranger to those licenses.
BIDI Vapor has received marketing and distribution approval in 11 foreign markets, including the U.K. and Russia. Those markets alone position BIDI Vapor and Kaival Brands to benefit significantly from concentrating their time and strategic efforts on penetrating these key international markets. Given the favorable dynamics in those markets, exploiting the lion’s share of the opportunity could happen faster than many expect. In fact, KAVL may feel at home in the United Kingdom, noting that market is one where Kaival Brands has always planned to introduce its BIDI Vapor products.
And like the U.S., the U.K. is no small market. It brings to KAVL the potential to generate billions of dollars in revenue, a score that could come quickly thanks to that country’s facilitating sector commerce more efficiently with fewer regulatory hurdles to clear. But here’s the better news- entry into the U.K. markets could be the revenue-generating catalyst inspiring rapid expansion across Europe, fueled by already-secured marketing and product approvals to distribute its entire BIDI® Stick product line (including non-tobacco flavors).
The U.S. Market Is Big, But Don’t Forget The U.K.
Those approvals are likely to expedite a planned expansion of sales in the U.K., which puts an estimated $2.5 billion ENDS market into near-term play. Remember, KAVL doesn’t need all or even half of that market to be successful. Earning even a small share of that market, say 20%, in a market expected to surpass $3.9 billion by 2023, would result in KAVL posting upwards of $780 million in revenues, a number that would surely add a sizable multiple to its current share price.
By the way, the demographics in the U.K. markets make it a perfect match for KAVL’s intentions. The target market in the U.K. is made up primarily of adult consumers, with an average consumer age of 35 to 45 years old. This is compared to an American demographic that ranges from 18 to 24 on average, which can be challenging to reach due to FDA marketing restrictions.
Moreover, while easy to say now, its product design and approach to marketing may resonate even more with U.K. consumers than adult smokers in the United States. ENDS consumers are primarily composed of current and former cigarette smokers, with less than 3.5% of the adult ENDS consumer population in the United Kingdom described as “never smokers.” Considering KAVL’s marketing focus toward current adult smokers looking for a superior alternative, this certainly works in KAVL’s favor.
Furthermore, surveys of adult smokers in the U.K. indicate they are more motivated than Americans to switch from cigarettes to vaping products. And with BIDI Vapor products serving as an authentic, effective alternative for adult smokers of traditional combustible cigarettes, these demographic differences and preferences could be potentially excellent news for KAVL’s business ambitions.
Incidentally, KAVL investors may not wait long for an update about those initiatives. KAVL has emphasized engaging in discussions to formalize international distribution agreements with its U.S. customers with global distribution capabilities. Therefore, despite FDA limitations on marketing certain products domestically, the billion-dollar market opportunities the FDA can’t control are indeed in play.
KAVL’s Opportunity Is Unique And Valuable
All tolled, the opportunities in play today can quickly transform KAVL from a small-cap to a large-cap. Keep in mind that the playing field in the ENDS sector has dramatically changed. So much so that the few left standing have the opportunity to earn an outstanding market share that would have been unthinkable just three years ago. And not just domestic share, international too.
What’s more, working with Philip Morris S.A. can possibly accelerate KAVL’s ambitions to penetrate large markets overseas. Not only that, that agreement may not remain exclusive, and investors can bet that PM competitors won’t give up market share if they have an opportunity to keep it. Thus, inking licensing, development, and branding deals may continue. If so, the money earned by producing products for other companies could also reach into the billions.
Thus, there’s a lot to like about Kaival Brands. In fact, with best-in-class products, the science supporting expansion through accurate marketing, a partnership with one of the world’s largest companies, and an ability to quickly expand market presence overseas, not appreciating KAVL and the investment opportunity at these prices may lead to a lost opportunity. And it’s one that, when the next piece of news comes out, may be gone forever, at least at these low prices.
Disclaimers: Shore Thing Media, LLC. (STM, Llc.) is responsible for the production and distribution of this content. STM, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by STM, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall STM, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by STM, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. STM, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, STM, Llc., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. STM, LLC has been compensated up to ten-thousand-dollars cash via wire transfer by a third party to produce and syndicate content for Kaival Brands, Inc. for a period of one month. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
Company Name: STM, LLC.
Contact Person: Michael Thomas
Country: United States